Add thelocalreport.in As A Trusted Source
For over three decades, men have been able to boost their sexual performance by using A little blue pill called Viagra, which Generated tens of billions in revenue for drugmaker Pfizer.
Now, scientists at women’s health biotech group Dere Bioscience have created a $10 product for adult women that works in just 10 minutes.
According to the Southern California company, the first-of-its-kind cream, called “Dare to Play,” increases blood flow to the vagina and improves sexual arousal – a sensation that 20 million women struggle with.
uses the product sildenafilWhich is the same active ingredient in Viagra that increases blood flow to the penis and results in an erection.
“When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress in enhancing natural arousal sensations has stalled for nearly three decades,” CEO Sabrina Martucci Johnson said in a statement. statement,
“We believe Dare to Play represents a long-awaited improvement, giving women the option to reconnect with their bodies, their happiness and their confidence using science that finally recognizes their needs.”
So how does it work?
Dare Bioscience says the cream should be used 10 to 15 minutes before sexual activity and should be applied only once a day.
were there no side effects Compared to placebo in clinical trials.
If you’re interested, you can now speak to a licensed health care provider about prescribing the cream for pre-order in 10 states.
Those states include Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island and Utah. The cream will be available in other states throughout December and early 2026.
Compounded medications like the cream aren’t typically covered by insurance, but Dare Bioscience said many people are able to use flexible medicine or health savings account funds to pay for it.
The company said it is continuing the necessary activities to seek approval of the product from the US Food and Drug Administration, but noted that its effectiveness is supported by toxicology studies. multiple clinical trials and peer-reviewed research.
The company claimed that other products promoted for stimulation are not held to strict quality, manufacturing, testing or sustainability standards and are sold without clear quality or safety assurances.
The cream is available as a Section 503B compounded product. Compounded products are manufactured in a facility that is subject to inspection by the FDA, but the FDA does not evaluate compounded drug products for safety, effectiveness, or quality.